We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low-Cost Genetic Test Can Distinguish Bacterial from Viral Infections

By LabMedica International staff writers
Posted on 19 Jul 2016
Upon identifying a set of seven relevant genes, a breakthrough rapid blood test has been developed that, with further development and testing, may soon enable physicians to determine if a patient has a bacterial or viral infection.

Too often there’s no easy way to diagnose whether a patient’s illness is bacterial or viral or if there is any infection at all. “A lot of times you can’t really tell what kind of infection someone has,” said lead author Timothy Sweeney, MD, PhD, engineering research associate, Stanford, “If someone comes into the clinic, a bacterial or a viral infection often look exactly the same.”

Image: The breakthrough 7-gene blood test may enable physicians to determine whether their patients have a bacterial or viral infection (Photo courtesy of Erin Kunkel and Stanford University Medical Center).
Image: The breakthrough 7-gene blood test may enable physicians to determine whether their patients have a bacterial or viral infection (Photo courtesy of Erin Kunkel and Stanford University Medical Center).

“The idea to look for a diagnostic test came from our previous paper in Immunity last year,” said senior author and team leader Purvesh Khatri, PhD, assistant professor, Stanford University Medical Center (Stanford, CA, USA), “In that paper, we found a common response by the human immune system to multiple viruses that is distinct from that for bacterial infections. We wondered whether we could exploit that difference to improve the diagnosis of bacterial or viral infections. But we needed a gene signature consisting of far fewer genes for the test to be clinically useful.”

The team used publicly available patient gene expression data to pinpoint 7 genes whose activity changes during an infection such that their pattern of activity can distinguish whether an infection is bacterial or viral. The 7-gene test is a vast improvement over earlier tests that look at the activity of 100s of genes. Because so few genes are involved, the new test will be cheaper and faster, while remaining accurate.

A study in Nepal co-authored by assistant professor Jason Andrews, MD, revealed that only 5% of patients who received antibiotics actually needed them, said Prof. Khatri. The Nepalese patients got antibiotic treatment because the drug was cheaper than trying to figure out if they actually needed it. “If we really want to make a difference,” Prof. Khatri said, “our test has to be more cost-effective than the drug itself.” That’s an important breakpoint.

The work is part of a global response to the need to reduce the use of antibiotics, driven in part by President Obama’s National Action Plan for Combating Antibiotic-Resistant Bacteria. Besides promoting evolution of drug-resistant microbes, antibiotics increase the risk of side effects such as tendon rupture or kidney damage, and can damage gut and other microbiomes essential to overall health.

The new test for bacterial infection faces two main hurdles before it can be made clinically available. First, it must be thoroughly tested in a clinical setting. Until now, the data and test results for this ongoing work have all come from preexisting, online digital data sets of gene expression from patients with different kinds of infections — not from current patients. The new study tested the 7-gene test on blood samples from 96 critically ill children, using a NanoString assay, and found that the test was accurate. This is a proof-of-concept but needs to be further validated in larger numbers of patients.

Second, the test needs to be incorporated into a device that can give a result in up to 1 hour. The preliminary NanoString version of the blood test takes 4-6 hours, rapid but too long for critically ill patients who, for example, have sepsis. So the researchers are working on a way to engineer the test to provide results in under an hour. The plan is to combine an 11-gene test (that they recently created a few months ago) with the newer 7-gene test. The 11-gene test reveals if the patient has an infection at all. If they do have an infection, the 7-gene test reveals if it is bacterial or viral. Both tests would be run simultaneously.

The researchers envision the two tests as a decision tree. “When you put the new 7-gene set together with the 11-gene set, we can make a decision tree that matches how a physician might think about a patient,” said Dr. Sweeney, “First we ask, ‘Is an infection present?’ Because some people present with an inflammation, a fever, a high heart rate, but it’s not due to an infection. Then we ask, ‘If so, what kind?’”

The study, by Sweeney TE et al, was published July 6, 2016, in the journal Science Translational Medicine.

Related Links:
Stanford University Medical Center


Gold Member
Hematology Analyzer
Swelab Lumi
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Chemistry Analyzer
MS100
New
FLU/RSV Test
Humasis FLU/RSV Combo

Latest Microbiology News

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Innovative Diagnostic Approach for Bacterial Infections to Enable Faster and Effective Treatment